Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study

BACKGROUND: In real-world practice, eribulin mesylate provides significant survival benefit, with a manageable safety profile in heavily pretreated patients with metastatic breast cancer (MBC). METHODS: In this prospective, open-label, multicentre, observational study we evaluated the effectiveness...

Descripción completa

Detalles Bibliográficos
Autores principales: Adamo, Vincenzo, Ricciardi, Giuseppina Rosaria Rita, Giuffrida, Dario, Scandurra, Giuseppa, Russo, Antonio, Blasi, Livio, Spadaro, Pietro, Iacono, Carmelo, Soto Parra, Hector J., Savarino, Antonino, Ferraú, Francesco, Zerilli, Filippo, Verderame, Francesco, Butera, Alfredo, Santangelo, Carlo, Franchina, Veronica, Caruso, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6923689/
https://www.ncbi.nlm.nih.gov/pubmed/31903098
http://dx.doi.org/10.1177/1758835919895755

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6923689/
https://www.ncbi.nlm.nih.gov/pubmed/31903098
http://dx.doi.org/10.1177/1758835919895755

Ejemplares similares